<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H1951136E45CD44CBB04F9BF9FF9CB63E" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 8192 IH: Nitazene Response Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2026-04-02</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 8192</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20260402">April 2, 2026</action-date><action-desc><sponsor name-id="T000490">Mr. Taylor</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Health and Human Services to issue guidelines for the purpose of addressing the problem of nitazene overdoses, and for other purposes.</official-title></form><legis-body id="HA24EE835D7AA44E283F30035CDA2E353" style="OLC"> 
<section id="H9D955C7CD584481886725C09ABEE9F49" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Nitazene Response Act</short-title></quote>.</text></section> <section id="H530BE16C93544C0ABE02C42C1E769172"><enum>2.</enum><header>Assistance in responding to nitazene overdoses</header> <subsection id="H788C43FE600B4405AFDA09C70E4D1548"><enum>(a)</enum><header>Guidelines</header> <paragraph id="H78BD7D0FA1F44CE0B08359014CF29D34"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services (in this section referred to as the <quote>Secretary</quote>) shall issue updated, evidence-based clinical guidelines (in this section referred to as the <quote>guidelines</quote>) for responding to nitazene overdoses.</text></paragraph> 
<paragraph id="H00C3AAC194B94907A8086C760534DD45"><enum>(2)</enum><header>Contents</header><text display-inline="yes-display-inline">The guidelines shall contain—</text> <subparagraph id="H13DE02A966F2429C941F7A97403A2701"><enum>(A)</enum><text display-inline="yes-display-inline">a description of best practices for responding to potential nitazene overdoses, including protocols for administering naloxone;</text></subparagraph> 
<subparagraph id="HD780B064493B438AAE8C2C635FA7993E"><enum>(B)</enum><text display-inline="yes-display-inline">guidance for emergency departments and hospitals in responding to nitazene overdoses;</text></subparagraph> <subparagraph id="HAFF791FE4CE54C6794498A4306EEFE46"><enum>(C)</enum><text display-inline="yes-display-inline">guidance for rural and volunteer emergency medical services systems in responding to nitazene overdoses; and</text></subparagraph> 
<subparagraph id="H31E889281B5D402BACB74559C3ED141D"><enum>(D)</enum><text>such other information as the Secretary determines appropriate.</text></subparagraph></paragraph> <paragraph id="H0084EED660C542509EA4C494948A861E"> <enum>(3)</enum> <header>Publication</header> <text>Not later than 180 days after the date of enactment of this Act, the Secretary shall publish the guidelines on the public internet website of the Department of Health and Human Services.</text>
        </paragraph></subsection> 
<subsection id="HB63AFCA3A2454261B08ADC661D7E085A"><enum>(b)</enum><header>Report to Congress</header><text display-inline="yes-display-inline">Not later than one year after the date of enactment of this Act, the Secretary shall submit to Congress a report containing the guidelines and a description of how the guidelines will assist in addressing the problem of nitazene overdoses.</text></subsection> <subsection id="H166EBE3ADD8A4DBBAB1C0D10AE7DA502"><enum>(c)</enum><header>Definitions</header><text display-inline="yes-display-inline">In this section:</text> 
<paragraph id="H84D764EE861A48C895DCD6F6EFD7320B"><enum>(1)</enum><header>Nitazene</header> 
<subparagraph id="H6576A92698B54AFA931FFCD3A381223F"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The term <term>nitazene</term> means benzimidazole-opioids, including any substance (including its salts, isomers, and salts of isomers) that has a chemical structure that is substantially similar to that of etonitazene or isotonitazene, including—</text> <clause id="H31AD501D45E64A5395563278096A873A"><enum>(i)</enum><text>a benzimidazole core substituted at the 2-position with a benzyl or substituted benzyl group;</text></clause> 
<clause id="H10BCA1E40685461E902B0723EC83059F"><enum>(ii)</enum><text>a basic nitrogen-containing side chain at the 1-position; and</text></clause> <clause id="H3066CA4B17C04B3B9E040FD1916C782A"><enum>(iii)</enum><text>exhibits agonist activity at the mu-opioid receptor.</text></clause></subparagraph> 
<subparagraph id="H0C41AF4866AC4EACA8D4219E6C6E3672"><enum>(B)</enum><header>Included substances</header><text display-inline="yes-display-inline">The term <term>nitazene</term> includes, at a minimum, the following: etonitazene, clonitazene, metonitazene, isotonitazene, protonitazene, butonitazene, etodesnitazene, flunitazene, N-pyrrolidino etonitazene, N-desethyl isotonitazene, and N-piperidinyl etonitazene.</text></subparagraph></paragraph> <paragraph id="H3EB618FFB25A45CAB1EFC13988860900"><enum>(2)</enum><header>Nitazene overdose</header><text display-inline="yes-display-inline">The term <term>nitazene overdose</term> means an overdose involving nitazene or any other ultra-potent synthetic opioid.</text></paragraph> </subsection> </section> 
</legis-body></bill>

